Matthias M Schweiger

Product Litigation Lawyer, Partner at Hogan Lovells @HLLifeSciences @HLProductLaw

[Matthias M Schweiger @mattmschweiger]

The U.S. Food and Drug Administration continues to explore the development of a standardized front of package nutrition labeling scheme by conducting consumer research. https://t.co/vIkr3bEUAn

[Matthias M Schweiger @mattmschweiger]

We are pleased to announce the return of partner, Rafael Ribeiro to our Miami office following an in-house position as Assistant General Counsel with the Global Ethics and Compliance Management team at The Walt Disney Company. https://t.co/a7CJs4KEZ9

[Matthias M Schweiger @mattmschweiger]

Arne Thiermann and Nicole Saurin talk about #artificialintelligence in the #medicaldevice industry on the first episode of the Talking the Cure Podcast Season 4.

Listen here
Spotify: https://spoti.​fi/3Krp0en
Apple: https://apple.​co/3ICBQps
Google:… https://t.co/a2sHieZb28

[Matthias M Schweiger @mattmschweiger]

For #pharmaceutical companies, the possibility of investment #arbitration is for the most part quite opaque. However, recent case law shows that the chances of success for investors are higher than expected. Partners Andrea Atteritano and Christian Di… https://t.co/r4xt49LXJ7

[Matthias M Schweiger @mattmschweiger]

How is your business addressing heightened ESG expectations? We interviewed 600 compliance leaders to get their views. Read our report to find out about the issues they identified, and our insights on how to navigate them. https://t.co/H4Ewky7uG7

[Matthias M Schweiger @mattmschweiger]

In this article, we analyze how FDA issued a revised draft guidance, “Charging for Investigational Drugs Under an IND: Questions and Answers,” adding information related to the need for submission of a statement by an independent certified public… https://t.co/eSRLJ7Lyyd

[Matthias M Schweiger @mattmschweiger]

Kristin Zielinski Duggan and industry leaders were recently featured in this POLITICO Future Pulse article, exploring the increased investment in #artificialintelligence for health care and questioning how government will regulate the #software. https://t.co/HarBK3SqWX

[Matthias M Schweiger @mattmschweiger]

Join us for the next installment of our Consumer Horizons webinars series which will focus on the ever changing and fast paced landscape of online and digital payments. Topics include; Digital currency in China; Buy Now Pay Later; and Cryptocurrency. https://t.co/8sRC8HPlsg

[Matthias M Schweiger @mattmschweiger]

An international team advised Covestro AG, one of the world's leading manufacturers of high-quality #plastics and their components, on the sale of its additive #manufacturing business to US-Israeli Stratasys Group. http://ow.​ly/fL9350KAju0

[Matthias M Schweiger @mattmschweiger]

Join partner Randy Prebula as he speaks at Tecan ’s AACC Annual Meeting in Chicago about the recent #regulatory landscape for lab developed tests in the U.S. and Europe under IVD-R.
#lifescience #healthcare #ivdr https://t.co/YD4ZTxLHYJ

[Matthias M Schweiger @mattmschweiger]

A recent amendment to the consumer code has changed the systematic framework of compliance requirements for consumer goods. The new rules, effective from 1 January 2022, will impact not only operators selling consumer goods but also manufacturers. https://t.co/wIQuVP1W1q

[Matthias M Schweiger @mattmschweiger]

Our Hamburg, Berlin and Munich lawyers discuss the new sustainability requirements under the German Packaging Act. Check out what's new below: https://t.co/qKXpXYhChy

[Matthias M Schweiger @mattmschweiger]

From June 26th, 2022, the “Italian Sunshine Act” entered into force. This is a piece of legislation aimed at preventing corruption and fostering transparency in the #health sector by imposing disclosure obligations on companies in the #pharmaceutical… https://t.co/cz4c27VlP1

[Matthias M Schweiger @mattmschweiger]

What’s on the #horizons for orthopedics devices? Why is the #orthopedics field still a little like the wild west of the #FDA? How will new #technologies reshape the conduct of #clinicaltrials? And finally, what are the do’s and don’ts when working with the FDA to develop a new…

[Matthias M Schweiger @mattmschweiger]

Allison Holt Ryan, Adam Cooke, Lance Murashige, Joe Cavanaugh, and Courtney Helt discuss how a jury finds defendant not negligent for response to data breach. Read more: https://t.co/rFyCaFaVmY

[Matthias M Schweiger @mattmschweiger]

Join the Hogan Lovells Food & Beverage and #ClassAction teams on Tuesday May 17, 2022 for the next webinar in our A Seat at the Table series. Our panelists will lead a discussion on key issues in food class action litigation, including the meaning of the… https://t.co/PibMTWU3UA

[Matthias M Schweiger @mattmschweiger]

Join us for a #Webinar on April 27, to learn about the U.S. SEC’s proposed rules requiring extensive climate-related disclosure, their implications for public companies, and what you can be doing now to prepare. #SEC ESG #ClimateChange… https://t.co/4B3Y1criGj

[Matthias M Schweiger @mattmschweiger]

On April 14, the U.S. Food and Drug Administration (FDA) released a new draft guidance to industry for increasing racial and ethnic diversity in clinical trials, titled "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial… https://t.co/VPVyceFLWH

[Matthias M Schweiger @mattmschweiger]

Register now for The MedTech Forum, where partner Fabien Roy will lead the “Ask The Expert” session on best practices for dealing with complex situations during #MDR conformity assessment procedures. #MTF2022 https://t.co/wlGKxN92YE

[Matthias M Schweiger @mattmschweiger]

Want to know more about artificial intelligence/machine learning based software as a medical device? Join partner Arne Thiermann’s “Ask The Expert” session at The MedTech Forum, which will also cover implications of the coming EU Artificial Intelligence… https://t.co/1SblvUMCTR